“The development of TE-6168, the novel thrombolytic fusion protein” was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan. The CDE case number is 115IDX02001.
Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), TE-8105, developed for the treatment of obesity. Conducted in Australia, the study demonstrated that TE-8105 is safe, well tolerated, and exhibits clear weight-loss potential, with only mild adverse
• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection site reactions seen with current therapies.• Strong Pharmacodynamic Activity: Robust, dose-dependent reduction of disease biomarker IGF-1, with 83% of high-dose participants achieving a >20% reduction, confirming therapeutic potential.• Significant Market Potential: Positioned for the US$10 billion long-acting
Immunwork announced that two ultra-long-acting drugs developed using innovative fatty acid bundles technology platform have received approval from the Australian Human Research Ethics Committee in May. TE-8105 targets obesity (including weight management), type 2 diabetes, and fatty liver disease, while TE-8214 targets neuroendocrine tumors and acromegaly. Both drugs have undergone initial dosing in low-dose subjects,
“The development of the novel drug, TE-8105, the glucagon-like peptide-1 receptor agonist” was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan. The CDE case number is 110IDX04007.
